Humanin Side Effects: Safety Signals and Warnings
Humanin safety concerns are compound-specific. The main listed side effects are Very limited safety data, No significant adverse effects reported in animal studies, and Potential for excessive anti-apoptotic signaling with chronic administration (theoretical concern for tumorigenesis). The main warning signals are Preclinical research only - no human clinical trials completed, Anti-apoptotic properties raise theoretical concerns about promoting tumor cell survival, and No established human dosing or safety data.
Direct Answer
Evidence for Humanin is too preliminary to support a research protocol with confidence. Data comes primarily from cell and rodent models, with a handful of observational human studies showing inverse correlations between Humanin levels and metabolic disease - not interventional data. The mitochondrial protective mechanism is interesting, but there is no actionable human protocol. NAD+ precursors have far more human interventional data for anti-aging applications.
- Evidence grade
- Level D
- Research status
- Preclinical
- Category
- Anti-Aging & Longevity
- Best for
- Mitochondrial protective peptide mechanistic research, neuroprotection models (preclinical only)
Reported Side Effects
- Very limited safety data
- No significant adverse effects reported in animal studies
- Potential for excessive anti-apoptotic signaling with chronic administration (theoretical concern for tumorigenesis)
Warnings
- Preclinical research only - no human clinical trials completed
- Anti-apoptotic properties raise theoretical concerns about promoting tumor cell survival
- No established human dosing or safety data
- Commercially available humanin peptides vary in purity and potency
Known or Plausible Interactions
- IGF-1 signaling modulators (humanin interacts with IGFBP-3)
- Apoptosis-modulating drugs (may interfere with intended pro-apoptotic effects of chemotherapy)
Regulatory Context
Not FDA approved. Not scheduled. Available as a research peptide.
Evidence Snapshot
| Evidence grade | Level D |
|---|---|
| Research status | Preclinical |
| Best supported outcomes | Neuroprotection (Level D), Cytoprotection and Anti-Apoptosis (Level D), and Metabolic Regulation (Level D) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Humanin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/humanin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.